Brain trauma affects millions. Learn about traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD) and how they impact civilians and Veterans.
Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.
Our approach is to build enabling platforms with strategic partners and to adopt a team science approach to fast-track solutions in years, not decades.
Cohen Veterans Bioscience would like to honor our military veterans by highlighting the ways we are transforming science to advance brain health.
Veterans have made sacrifices for our country – they may engage in combat and experience physical and/or psychological trauma, be separated from their families and friends for lengthy periods and endure highly stressful circumstances during and post-service. In totality, they face unique challenges for maintaining and restoring brain health.
Many veterans have experienced and are suffering with the invisible wounds of war (post-traumatic stress disorder (PTS/PTSD) and Traumatic Brain Injury (TBI) and on top of this we are facing increasing rates of suicide.
Yet, for the past 17 years, there have not been any new FDA-approved treatments to address PTSD. Nor are there any currently available objective diagnostics or biomarkers for PTSD or for the chronic neuropsychiatric effects of TBI.
On this Veterans Day, Cohen Veterans Bioscience would like to honor our military veterans by highlighting the ways we are transforming science to advance brain health.
Adaptive Platform Trial for Post-Traumatic Stress Disorder
Cohen Veterans Bioscience was awarded a contract from the U.S. Department of Defense Medical Research and Materiel Command to establish a clinical trial infrastructure for PTSD pharmacotherapeutics and to conduct one of the first studies in the field utilizing innovative adaptive platform trial design.
Cohen Veterans Bioscience will collaborate with Parexel Biotech, a new division of Parexel for the study. Parexel Biotech will provide clinical trial implementation services over a multi-year period. We are delighted to be part of this important adaptive platform trial exploring a precision medicine approach for the treatment of PTSD,” says Parexel CEO Jamie Macdonald. We look forward to partnering with CVB on this innovative trial design in the brain disorders arena and to contributing to this important new therapy, which has significant potential to benefit patients.”
Learn more about the strategic collaboration and the Adaptive Clinical Trial, which will start in 2020.
Developing a Research Roadmap for Traumatic Brain Injury
The Brain Trauma Blueprint is a strategic roadmapping effort facilitated by a series of State of the Science Summits aimed to accelerate an era of personalized medicine for survivors of brain trauma.
This year CVB convened global thought leaders to collaborate and assess the gaps in the science and ways to work toward new paths to treatment for Traumatic Brain Injury(s).
As part of the effort to include the patient perspective in our research, CPT John E. Cebak, DO, PhD, KY Army National Guard discusses his experiences with TBI and PTSD I am a different person. I struggle with living in a fog, problems with attention, concentration, balance, vision, communication and nightmares.”
The blueprint is designed to identify the underlying biology of these symptoms and provide personalized treatment options for our Veterans like Johnny and all patients living with these invisible wounds. Leaders are finalizing the recommendations from the summit and the outcome will be published in 2020.
Global PTSD Genetics Program
Identifying Genetic Links to Post-Traumatic Stress Disorder
In collaboration with The Stanley Center for Psychiatric Research at the Broad Institute at MIT and Harvard, we announced findings from a study published in Nature Communications.
Biomarker Establishment for Superior Treatment (BEST)
Advancing a Precision Therapeutic Approach to PTSD Diagnosis & Treatment
In April 2019 we announced findings from the first study identifying a PTSD brain imaging biomarker. This is the first study to demonstrate that PTSD patients can be reproducibly sub-divided into distinct groups based only on their biological signature. An important first step in advancing a precision therapeutic approach for PTSD, the study revealed that a patient’s biotype may determine which PTSD treatment could work best. With this biomarker, we may be able to identify which patients will respond to psychotherapy and which will not, giving clinicians a powerful tool to personalize therapy and to guide people towards the most effective treatment options for them.
Coalition to Heal Invisible Wounds
Progress on Veterans Brain Health Advocacy
The Coalition to Heal Invisible Wounds is a collaboration of members committed to solving brain health issues important to veterans, including veterans advocacy groups, non-profit research foundations, and pharmaceutical companies.
With a shared passion for improving PTSD and TBI outcomes through advocacy, the Coalition educates Congress on the top brain health care concerns to shape how government research dollars and resources are allocated.
As a member of this Coalition, our President and CEO, Dr. Magali Haas testified in front of the House Committee Veterans’ Affairs Subcommittee on Health hearing, “Beyond the Million Veterans Program: Barriers to Precision Medicine” about the urgent need for policy reforms to widen and expedite the pipeline for new therapies and diagnostics to treat PTSD, traumatic brain injury (TBI) and suicide prevention. To watch the hearing, click here.
Veterans Advisory Council
Representing, Advocating and Supporting Veterans’ Interests
Cohen Veterans Bioscience is sponsoring the formation of a Veterans Advisory Council (VAC) to ensure that we deliver meaningful results for Veterans through data-driven science and advocacy. The VAC will serve as a voice by providing advice and strategic recommendations for CVB’s mission and objectives.
Cohen Veterans Bioscience and 22 Jumps Announce Parachuting with Purpose: Recognizing the Epidemic of Veterans Suicide as a Result of Traumatic Brain Injury (TBI) and PTSD
Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.
Manage Cookie Consent
We use cookies to optimize our website.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.